AI News Archive: June 12, 2026 — Part 12
Sourced from 500+ daily AI sources, scored by relevance.
- NeuroCLI
AI ReImagined
- Agent Tool Intelligence
You built an MCP server. Does anyone know it exists?
- CanisMentor
AI Dog Trainer
- Vitalsy AI
The AI Health Assistant and Tracker
- ASE(Auditome Sovereign Engine)
AI keeps moving. ASE keeps it accountable.
- BeadPattern
BeadPattern is a free AI-powered bead pattern generator
- 开源AI衣键去
ai绘画
- Flick.AI
AI video generator, face swap, AI image editor,pose transfer
- ECHO-R
Persistent AI personality with memory continuity
- Gurucle
Predict the day. Climb the ranking. No money. Just brains.
- Tuto
Predict the world cup, get ranked globally
- youtube-roast
avage AI roast for any YouTube channel.
- Noronin - Know your brain
Finally understand what's happening inside your brain
- EZJob: AI Job Matching for France
AI job matching: score CVs vs offers, letters in 30sec
- GoodMoat
AI Stock valuation & data platform for every stock
- Hostinger | AI Website Builder
Create stunning websites instantly with AI.
- Lium AI
AI for complex data
- PUNKU.AI
Lovable for AI Agents
- MIRA by ThinCorp
Swiss-made AI for intelligent customer service.
- OutlierKit
Enter one channel, see the entire niche.
- Apex AI
Bilingual AI receptionists for dental practices and med spas.
- ResearchMonkey AI | YouTube Summarizer
Save Hours of Research in Seconds with 40+ AI Tools
- VlogMe AI
Turn any portrait into a realistic talking avatar video.
- DescribeImage.io
AI-powered image and video understanding tool.
- AI Image Combiner
Combine people, products, backgrounds with best-in-class AI.
- WebsitePublisher AI
Your AI builds a full app, right from your phone
- SayEvent
The first AI-native ticketing platform
- Hostinger | Hermes Agent
Deploy self-improving AI agents with one-click Docker setup.
- Adsmaker.ai
Adsmaker.ai
- Roger
Roger
- MaxAEO
MaxAEO
- Google promised never to build AI weapons; then director René Mayrhofer resigned when the tech giant broke that promise
René Mayrhofer, Google's director for Android platform security, has resigned over the company's decision to supply AI technology to the US military for classified work — and he is not staying quiet about why.
- Mistral AI seeks 3 billion euros to fund its European AI push
French AI startup Mistral AI is negotiating a new funding round of around 3 billion euros at a valuation of approximately 20 billion euros. The article Mistral AI seeks 3 billion euros to fund its European AI push appeared first on The Decoder .
- XL-MS-Guided Structure Prediction of Disordered Encephalitozoon hellem Proteins
Microsporidia such as Encephalitozoon hellem are obligate intracellular human parasites that remain genetically intractable, limiting functional characterization of their proteomes. Structural studies based on homology-based modeling and the use of deep learning algorithms of microsporidian proteins also remain limited because most have little to no sequence similarity to proteins with solved structures. To address these limitations, we developed an approach that incorporates cross-linking mass spectrometry (XL-MS) data into structure prediction. XL-MS data provides upper bound distance constraints that can be incorporated into protein deep-learning based modeling and subsequent docking. Using this approach, we generated a model for two interacting E. hellem spore wall proteins Spore Wall Protein 1B (Swp1b) and Endospore Protein 1 (EnP1), with no clear homologs outside of microsporidia, and which contain several disordered regions. These proteins are extremely abundant spore wall proteins of microsporidia and previously were not known to interact with one another. The resulting model not only is consistent with the experimental crosslinks used to generate the model but was subsequently confirmed by independently generated XL-MS data. The described AlphaLink-Modeller framework for structure prediction is particularly well suited to proteins with limited homology and/or substantial flexible regions, given they adopt a defined structural state within a biological context, thereby extending integrative modeling approaches to previously inaccessible targets.
- Mechanistic simulation identifies predictive dose-dependent biomarkers of propofol anesthesia
Understanding how receptor-level pharmacological modulation reorganizes large-scale brain circuits remains a central challenge in neuropharmacology. We introduce a multiscale mechanistic model with explicit core-matrix thalamocortical architecture, driven solely by GABA-A modulation without parameter fitting to any anesthesia data, to examine how propofol reorganizes brainwide activity from individual receptors to systems-level circuits. The model exhibits anesthetic effects spanning individual synaptic conductances to widespread changes in spiking, field potentials, and coherence. Without training on any task-specific data, our simulation of sensory processing in a standard auditory oddball paradigm matches independent macaque datasets. The same simulation, unmodified, also reproduces changes to functional connectivity in anesthetized humans, exhibiting selective attenuation of matrix thalamocortical loops relative to core loops. Most importantly, the simulation identified a dose-dependent biomarker of propofol concentration - elevated residual inter-stimulus cortical activity - that was subsequently confirmed in empirical macaque data where it had previously gone unnoticed. This simulation-first discovery, arising from mechanistic circuit dynamics rather than statistical comparison of clinical populations, illustrates a generative framework for translating receptor-level modulation into circuit-scale biomarkers with potential applications across predictive neuropharmacology.
- Order-Based Bayesian Network Modeling of Early Detection and Post-Diagnosis Control for Cardiovascular Disease Risk in Type 2 Diabetes
Patients diagnosed with type 2 diabetes (T2D) are at increased risk of developing cardiovascular disease (CVD), the leading cause of morbidity and mortality in this population. Early detection and glycemic control within the first year after diagnosis reduce CVD risk. However, gaps remain in how to operationalize early detection of T2D using Electronic Health Record (EHR) data and quantify its relationship with subsequent CVD risk using longitudinal observations. We developed a probabilistic graph model to analyze the interdependencies between early detection of T2D, post-diagnosis glycemic control, and CVD occurrence. Using a temporally structured Bayesian Network (BN) learned from EHR data of 9,450 primary care patients between 2017 and 2023, we quantified probabilistic dependencies between demographics, diagnostic delay surrogates, glycemic control, and post-diagnosis CVD occurrence. Percentile based thresholds defined risk groups, where individuals with predicted probabilities in the bottom decile ([≤] 10th percentile) were classified as low risk, and those in the top decile ([≥] 90th percentile) as high risk. Results demonstrated heterogeneity in predicted risks across glycemic and cardiovascular outcomes. Predicted probability of developing CVD within the first year after T2D diagnosis ranged from a mean of 5.2% in the low-risk group to 28.9% in the high-risk group, while predicted probabilities of mean Hemoglobin A1c (HbA1c) [≥] 8% during the first year post-diagnosis ranged from 1.6% in low-risk to 55.1% in high-risk group. Patients with HbA1c at diagnosis [≥] 8% had higher predicted probabilities of first-year post-diagnosis mean HbA1c [≥] 8% (53.3% vs. 1.9%) and high HbA1c coefficient of variation (18.7% vs. 3.1%) compared with those with HbA1c [≤] 6.5%. Incorporating early clinical outcomes refined later risk predictions, with long-term CVD risk reaching 33.5% among high-risk individuals. The proposed model achieved predictive performance comparable to conventional machine learning approaches while providing interpretable relationships for risk stratification in primary care populations.
- Heterogeneity of Treatment Effect of Aspirin and Clinically Significant Bleeding in Older Adults
Aim: The global population of older adults is growing, and older age is linked to higher bleeding risk. Although guidelines discourage aspirin for primary prevention in healthy older adults due to bleeding harms outweighing benefits, many continue taking it without a clear indication. It remains unclear whether all older adults face uniform aspirin-related bleeding risk or if certain subgroups are more vulnerable. Methods: We analyzed data from 19,114 ASPREE trial participants to develop machine learning models using 116 baseline variables. Random forest (RF) and random survival forest (RSF) models predicted 5-year bleeding risk, and participants were stratified into low, intermediate, and high-risk groups based on the 20th and 80th percentiles of predicted risk. We assessed heterogeneity of treatment effect (HTE) by testing treatment-by-risk group interactions on the relative scale using Fine-Gray models, and on the absolute scale using observed 5-year cumulative incidence rates. Results: Over a median follow-up of 4.7 years, 626 major bleeding events occurred. The RF model had moderate discrimination (AUC = 0.65, 95% CI: 0.63-0.67) and good calibration (Brier = 0.032, 95% CI: 0.029-0.034). Statistically significant HTE was observed on the relative scale, with the greatest relative increase in bleeding risk seen in the low-risk group (subdistribution hazard ratio = 2.26, 95% CI: 1.27-4.01). On the absolute scale, low-risk participants experienced higher bleeding with aspirin (absolute risk difference (ARD) = 1.17%, 95% CI: 0.37-1.95), but heterogeneity in ARDs was not statistically significant (Cochran's Q p > 0.45). Similar findings were observed when using the RSF model. Conclusion: Participants at lowest baseline bleeding risk experienced the greatest relative increase in bleeding risk with aspirin therapy. We found statistically significant heterogeneity in treatment effects on the relative but not absolute scale. These findings support an individualized, risk-based approach to aspirin therapy decision-making in older adults.
- Agreement of an AI tool for joint space width measurement in radiographic knee osteoarthritis: data from the LOSEIT trial
Background and rationale: Knee osteoarthritis (KOA) is a leading cause of lower limb disability worldwide, characterized by functional limitations, stiffness and pain. The incidence of KOA is especially tied to age and obesity. It is a disabling disease that often makes patients less physically active, thus increasing the risk of other diseases and mortality1. The clinical diagnosis of KOA is based on the symptoms and functional limitations of the joint. The diagnosis is usually supported with a radiograph (X-ray) of the weight-bearing knee. Radiographic features, such as Kellgren-Lawrence grade, are used as eligibility criteria for clinical studies while other features, such as joint space width (JSW), are used as endpoints for structural KOA progression2,3. While the use of these radiographic features is standard in academia, the use of JSW as a structural biomarker has received criticism. Critics point out that JSW is an indirect and projection dependent measure of cartilage deterioration which is sensitive to technical factors such as the angulation of the X-ray beam and the positioning of the knee. Small differences in these factors can alter the measured joint space and may not reflect true disease progression4,5. Despite limitations, minimum joint space width (mJSW) remains as one of the most widely used structural biomarkers in KOA trials and is currently one of the only structural imaging accepted in regulatory guidance as evidence of disease modification in OA drug development3. For JSW to be reliable and consistent in determining the advancement of KOA, the use of fixed-flexion devices is crucial to reduce the risk of unwanted narrowing or widening of the radiographic joint space width6,7. The LOSEIT trial, which the present study is based on, acknowledges the angulation problem and uses a standard clinical fixed-flexion device in weight-bearing PA views to get reliable JSW results8. Historically, a radiologist would draw on and grade radiographs of the knee-joint to extract the features. However, manual reading and annotation is time consuming with notable interobserver variance9. With increasing computational power and the use of deep neural networks, off-the-shelf artificial intelligence (AI) tools have become available for automatic extraction of radiograph features. Automation would free up time from radiologists and provide more consistent measurements due to the reproducible nature of the models10. These tools have received regulatory approval for commercial use, however, regulatory approval does not guarantee uniform or bias free performance when used on real-world data11. Furthermore, in a large multi-hospital chest X-ray study, Zech et al., showed that convolutional neural networks achieved worse results on data from other hospitals than on the original hospitals in which it was tested12. This highlights the risk of overestimating the accuracy of AI tools when only internally validated. It is therefore apparent that external validation is required when testing these AI models. Objectives: The aim of this analysis is to evaluate the agreement of a commercially available AI tool for measuring JSW with the best practice radiologist annotation in the tibiofemoral joint of the knee in radiographs stabilized with a fixed-flexion device and acquired as part of a clinical trial. Methods: This study is a secondary analysis of the data from the LOSEIT trial, a randomized, double-blind, placebo-controlled, single-center trial, where patients were randomized to either liraglutide or identically appearing placebo after an initial weight-loss period to investigate the effects on KOA. Radiographs of the tibiofemoral joint were acquired at enrollment (week -8) and at end-of-trial (week 52) for a total acquisition-to-acquisition time of 60 weeks13. The primary analysis will assess agreement between AI-derived and reference-derived change in JSW from enrolment to follow-up. Change will be calculated as follow-up minus enrolment separately for the AI tool and the reference measurement. The main measure of interest will be the change in medial minimal JSW (mmJSW), with change in lateral minimal JSW (lmJSW), medial fixed JSW (mfJSW) and lateral fixed JSW (lfJSW) as secondary measures. This study will follow an equivalence framework using the two one-sided tests (TOST) approach with a Bland-Altman analysis as the main outcome. The equivalence margin will be set at {delta} = 0.5 mm. Agreement consistent with equivalence will be considered established if the upper limit of the 95% confidence interval (95% CI) for the upper limit of agreement (LoA) and the lower limit of the 95% CI for the lower LoA are within the established margins. The reference JSW will be the average measurement of two independent resident radiologists. If there is a mismatch in the measurements of more than 0.40 mm between the two radiologists, the radiologists will re-annotate the case independently. If the difference remains greater than 0.40 mm, a musculoskeletal radiology consultant will review the radiograph and establish the reference JSW. The index test will be the measurements output by the AI tool. Populations: Patients aged 18 to 74 with symptomatic knee osteoarthritis, radiographically confirmed KL grade 1-3, with a BMI [≥]27, motivated for weight loss and in accordance with the LOSEIT trial inclusion criteria Further statistical details Sample size: Not applicable as this is a secondary analysis. Framework: This is an agreement study assessing the equivalence of a commercially available AI tool for radiographic evaluation of knee osteoarthritis with best practice radiologist measurements. Confidence intervals and P values: All 95% confidence intervals and P-values will be two-sided. Statistical software: SAS Studio and/or R version 4.2.2 (or newer).
- Spatially resolved T cell receptor tracking reveals γδT cell localization to tumor-rich regions in high-risk neuroblastoma: A Report from the Children's Oncology Group
High-risk neuroblastoma (HRNB) is a leading cause of pediatric cancer death. Current therapies center on intensive multimodal treatment including anti-GD2 therapy, with growing interest in harnessing T cell-mediated immunity. How T cells and their receptors (T-cell receptors, TCRs) are spatially organized and function within tumors remains poorly defined. To assess whether intratumoral location influences clonotype-specific T cell states, we profiled TCR repertoires across blood and tumor samples from 37 patients with HRNB using longitudinal bulk TCR sequencing. In a nested subset of 5 patients with paired pre- and post-therapy tumors, we integrated spatial transcriptomics with in situ TCR profiling. Across all tumors, T and B cells preferentially co-localized in immune-rich regions and showed reduced proximity to neuroblast cells. Despite this compartmentalized architecture, {gamma}{delta}T cells were more evenly distributed across tumor sections and showed greater proximity to neuroblast-rich regions than other T cell subsets. Within TCR clonotypes, spatial location was associated with distinct transcriptional states, with immune-rich regions supporting more progenitor-like programs. These findings identify spatial context as a key determinant of phenotype clonotype-specific T cell phenotype and highlight {gamma}{delta}T cells cells as a spatially distinct population with potential roles in neuroblastoma tumor-immune interactions.
- ShortFormed
Turn your long videos into shorts in minutes
- High-volume Prompt Miner for free
Discover the high-value prompts your customers are asking AI
- Hintder
Your AI dating wingman
- Artificial intelligence-assisted ganglion cell detection in Hirschsprung's disease: A comparative evaluation of two deep learning approaches
Background. Definitive diagnosis of Hirschsprung's disease (HD) requires pathological identification of enteric ganglion cells. This process is time-consuming and subject to inter-observer variability. Artificial intelligence (AI) tools have the potential to standardize and accelerate this workflow, but no study has determined which AI approach best serves intraoperative HD pathology diagnostics. Method. This study compared the U-Net and You Only Look Once version 26 (YOLO26) frameworks for ganglion cell detection using a single-centre retrospective dataset of 54 whole-slide images (WSIs) from rectal biopsies. WSIs were tiled into 397,731 image patches (128x128 pixels), further partitioned into training (70%), validation (15%), and testing (15%) sets. Models were evaluated on tile- and patient-level diagnostic metrics and processing latency. Results. The U-Net achieved a tile-level sensitivity of 82.9%, showing no statistically significant difference compared to YOLO26 (79.1%; p = 0.097). However, YOLO26 demonstrated a statistically significant advantage in tile-level specificity (96.1% vs. 93.9%; p < 0.001) and reduced mean inference latency (7.64 ms vs. 11.57 ms/tile). At the patient level, both models achieved 100% diagnostic sensitivity. Despite low patient-level specificity (0.0% U-Net; 11.8% YOLO26), the tissue-level diagnostic burden of false positives was 6.00% for U-Net and 3.50% for YOLO26. Conclusion. The U-Net is preferred when nominal gains in sensitivity are prioritized, while the YOLO26 is an alternative that optimizes efficiency and false positive suppression. Both models serve as robust screening filters to augment the pathologist's workflow and should be selected based on workflow requirements. Prospective validation on larger, multi-centre datasets is required before clinical implementation.
- Conversational Artificial Intelligence-Enabled Precision Oncology Reveals Context-Specific TGFβ and JAK/STAT Alterations in Pancreatic Cancer
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive molecular complexity, profound stromal remodeling, and limited responsiveness to systemic therapies. Although gemcitabine-based regimens remain widely utilized, the molecular pathways that influence treatment-associated biological variation are incompletely understood. The TGF{beta} and JAK/STAT signaling networks are recognized regulators of tumor progression, immune modulation, and therapeutic resistance; however, their genomic architecture in clinically stratified PDAC populations remains poorly defined. Methods: We employed a conversational artificial intelligence-driven analytical framework to investigate TGF{beta} and JAK/STAT pathway alterations in a cohort of 184 PDAC patients. Clinical and molecular data were integrated to generate age- and treatment-stratified cohorts, enabling pathway-level and gene-level analyses according to gemcitabine exposure. Findings generated through AI-assisted interrogation were subsequently evaluated using conventional statistical approaches. Results: TGF{beta} pathway alterations were identified in approximately one-quarter to one-third of tumors across clinical subgroups and demonstrated relatively stable frequencies regardless of age at diagnosis or gemcitabine treatment status. Gene-level analyses revealed that pathway disruption was predominantly driven by recurrent alterations in SMAD4, with additional low-frequency events involving TGFBR1 and TGFBR2. Notably, TGFBR2 mutations were significantly more frequent among late-onset PDAC patients receiving gemcitabine compared with untreated late-onset patients (8.8% vs. 1.4%; p = 0.04), suggesting a potential treatment-associated enrichment. In contrast, JAK/STAT pathway alterations were rare throughout the cohort, with only isolated mutations observed in pathway components including JAK1, JAK2, JAK3, STAT1, STAT3, and related regulatory genes. No significant differences in JAK/STAT alteration frequencies were identified according to age or treatment exposure. Conclusions: TGF{beta} and JAK/STAT pathways exhibit distinct genomic architectures in PDAC. TGF{beta} pathway disruption represents a recurrent feature of disease biology, largely driven by SMAD4 alterations, while TGFBR2 enrichment in gemcitabine-treated late-onset tumors suggests a potential context-specific association worthy of further investigation. Conversely, genomic alterations within the JAK/STAT pathway are uncommon, indicating that pathway activity may be regulated predominantly through non-genomic mechanisms. These findings demonstrate the utility of conversational artificial intelligence agents for rapid, scalable, and clinically contextualized pathway interrogation and support future studies integrating multi-omic data to refine precision medicine strategies in PDAC.
- A Machine Learning Pipeline for Scalable Annotation of Patient-Ventilator Dyssynchrony from Bedside Ventilator Data
Objective: Patient-ventilator dyssynchrony (PVD) is a common and clinically consequential problem in critically ill patients receiving invasive mechanical ventilation. Yet automated identification of PVD subtypes at scale remains an unmet clinical need, owing to the lack of large annotated bedside waveform datasets. Methods: We developed and validated a semi-supervised algorithm for automated annotation of PVD. In two medical ICUs at a tertiary academic center, bedside devices continuously collected airway flow and pressure waveforms from the ventilators. We developed a software interface with an information retrieval system that grouped similar breaths for expert human review, yielding 1,542,296 labeled breaths across eight categories: 2 labels for breath delivery mode, 5 labels for PVD subtypes, and 1 label denoting a normal breath. Two pulmonary physicians with expertise in ventilator training and education provided the expert reference labels. We trained an initial classification model on a model-derivation set of 771,148 breaths (divided into training and validation) and evaluated it on a hold-out test set of 771,149 breaths A semi-supervised approach was utilized to extend labeling to an additional 12,965,000 unlabeled breaths. Results: The supervised model performed well across all labels, with Macro-F1 scores between 0.96 and 1.00. Semi-supervised learning across 12 rounds expanded the training set from 771,148 to 8,563,995 breaths without significant performance degradation. Conclusion: We developed a practical and scalable system for automated PVD annotation that performed well across all subtypes. This work provides a reproducible foundation for automated PVD labeling to support the development of machine-learning-based clinical decision support systems for identifying patient-level asynchrony.
- Disentangling Confounders from Pathology in Long-COVID Trajectory Prediction for Women: An Interpretable Large-Language-Model Approach
Objective. Post-acute sequelae of SARS-CoV-2 infection (PASC, "Long COVID") dispropor- tionately affects women, in whom hallmark symptoms--insomnia, fatigue, palpitations, cogni- tive difficulty--overlap with comorbidities and hormonal transitions such as menopause. This diagnostic overlap is a confounding problem: models that forecast future symptom severity risk attributing baseline physiological noise to viral pathology. We ask whether an interpretable, causally disentangled language model can separate true pathological signal from such con- founders while remaining competitive with strong predictors of future PASC severity
- The AI Price War Is Here, Piling Pressure on OpenAI and Anthropic
Startups and tech giants alike are mixing and matching AI models to avoid the premium prices charged by industry leaders
- German court holds Google liable for fake AI answers
Judges in Bavaria drew a distinction between standard search engine results and AI-generated summaries. They ruled that tech giants themselves are responsible for the content of answers provided by AI.
- Claux
Monitoring and observability tool for Claude Code
- She confided in ChatGPT the night of her suicide. Now, her mother is suing OpenAI.
A mother has filed a lawsuit against OpenAI, alleging the chatbot's design led to her daughter's suicide.